SCHEDULE: FMR LLC & Abigail Johnson Boost Vaxcyte Stake to 10.1%
Schedule 13G Amendment
FMR LLC and Abigail P. Johnson have reported a 10.1% beneficial ownership stake in Vaxcyte Inc. common stock.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 13,132,825.71 shares of Vaxcyte Inc. common stock.
- This ownership represents 10.1% of the total outstanding common stock of Vaxcyte Inc.
- FMR LLC holds sole voting power over 13,090,519.00 shares and sole dispositive power over 13,132,825.71 shares.
- Abigail P. Johnson, as a control person of FMR LLC, is deemed to beneficially own the same 13,132,825.71 shares with sole dispositive power.
- The filing is an Amendment No. 8 to a Schedule 13G, indicating an update to a previously reported ownership position.
Sentiment
Score: 6
Explanation: The filing indicates significant and continued institutional investment in Vaxcyte Inc. by a major asset manager, which is generally a positive signal, though it does not provide operational or financial performance details.
Positives
- FMR LLC, a major asset manager, and Abigail P. Johnson, a prominent figure, maintain a significant 10.1% beneficial ownership stake in Vaxcyte Inc., signaling continued institutional confidence.
- The substantial stake of 13,132,825.71 shares suggests a long-term investment perspective from a sophisticated investor.
Negatives
- The filing itself does not present any negative information regarding Vaxcyte Inc.'s operations or financial health, as it is purely an ownership disclosure.
Risks
- This filing, being an ownership disclosure, does not detail specific risks related to Vaxcyte Inc.'s business operations or financial performance.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Vaxcyte Inc.'s future performance or strategic direction.
Industry Context
This filing reflects a significant institutional investment in the biotechnology sector, indicating continued interest from major asset managers in companies like Vaxcyte Inc. However, it does not provide specific details on broader industry trends or competitive positioning.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Control Structure Disclosure (FMR LLC) | The filing details the internal control structure of FMR LLC, noting that members of the Johnson family, including Abigail P. Johnson, are predominant owners of Series B voting common shares (49% voting power) and have a shareholders' voting agreement, forming a controlling group for FMR LLC. | NA | This information pertains to the governance of the reporting entity (FMR LLC) and not to Vaxcyte Inc.'s corporate governance directly. |
Stakeholder Impact
- Shareholders: The continued significant institutional ownership by FMR LLC may instill confidence among existing and potential shareholders, suggesting a vote of confidence in Vaxcyte Inc.'s long-term prospects.
- Company Management: The sustained investment from a major asset manager could be seen as validation of the company's strategy and management.
Key Dates
| Date | Description |
|---|---|
| 08/29/2025 | Date of event which requires filing of this statement. |
| 09/05/2025 | Date of signature for FMR LLC and Abigail P. Johnson on the filing. |
Recommendation
holdThis Schedule 13G filing primarily reports a significant beneficial ownership stake by FMR LLC and Abigail P. Johnson in Vaxcyte Inc. While a 10.1% stake from a major institutional investor can be interpreted as a positive signal of confidence, the filing itself does not provide sufficient operational, financial, or strategic details about Vaxcyte Inc. to warrant a 'buy' or 'sell' recommendation. Investors should consider this information as an indicator of institutional interest but rely on comprehensive fundamental analysis for investment decisions. Therefore, a 'hold' recommendation is appropriate based solely on this filing.
Keywords
Vaxcyte Inc, VAXCYTE, FMR LLC, Abigail P. Johnson, Common Stock, Institutional Ownership, Schedule 13G, Biotech, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.